Patents by Inventor David James Craik
David James Craik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8354372Abstract: This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C-terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded in pairs to form two disulfide bonds, wherein the N-terminus of the corresponding linear/non-cyclised conotoxin peptide is linked to the C-terminus by a peptide linker, in a vehicle which is pharmaceutically suitable for oral or enteral administration.Type: GrantFiled: April 3, 2007Date of Patent: January 15, 2013Assignee: The University of QueenslandInventors: Richard Clark, David James Craik
-
Patent number: 8242250Abstract: The present invention relates to a novel nucleic acid molecule encoding an amino acid sequence, which is capable of forming a cyclic structure. Cyclization may occur within a cell or cell membrane, or linear forms of the molecules may be circularised or partially circularised, in vitro using isolated enzyme systems or chemical means. The cyclised amino acid sequence is generally in the form of a stabilized folded structure such as acyclic knotted peptide, polypeptide or protein or functional equivalent. The nucleic acid molecules and cyclic and linear peptides are useful inter alia in the generation of molecules having animal or plant therapeutic properties, as well as in a range of diagnostic, industrial and agricultural, including horticultural, applications. Of particular importance is the use of these molecules in the protection of plants, such as crop plants, from pest and/or pathogen infestation.Type: GrantFiled: August 26, 2009Date of Patent: August 14, 2012Assignees: The University of Queensland, Hexima LimitedInventors: David James Craik, Marilyn Anne Anderson, Cameron Victor Jennings
-
Publication number: 20110244564Abstract: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the present invention provide a molecular framework for the introduction of particular amino acids or heterologous amino acid sequences to facilitate the presentation of biological activities associated with these heterologous amino acid sequences. The molecular framework of the present invention may be naturally cyclic or may be a cyclized derivative of a linear molecular or may be a linear derivative of a cyclized molecule. The present invention contemplates the use of the molecular framework with or without particular ammo acids inserted or substituted thereon for the treatment of or prophylaxis of disease conditions in animals, mammals (including humans) and plants.Type: ApplicationFiled: June 14, 2011Publication date: October 6, 2011Applicant: THE UNIVERSITY OF QUEENSLANDInventors: David James Craik, Norelle Lee Daly, Clement Waim-Kunduane Waine
-
Publication number: 20100298528Abstract: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the present invention provide a molecular framework for the introduction of particular amino acids or heterologous amino acid sequences to facilitate the presentation of biological activities associated with these heterologous amino acid sequences. The molecular framework of the present invention may be naturally cyclic or may be a cyclized derivative of a linear molecular or may be a linear derivative of a cyclized molecule. The present invention contemplates the use of the molecular framework with or without particular amino acids inserted or substituted thereon for the treatment of or prophylaxis of disease conditions in animals, mammals (including humans) and plants.Type: ApplicationFiled: March 1, 2010Publication date: November 25, 2010Applicant: THE UNIVERSITY OF QUEENSLANDInventors: David James Craik, Norelle Lee Daly, Clement Waim-Kunduane Waine
-
Publication number: 20100120670Abstract: This invention relates to an oral or enteral pharmaceutical preparation comprising at least one synthetically cyclised alpha-conotoxin peptide having an amide cyclised backbone such that the peptide has no free N- or C-terminus, said peptide having the ability to inhibit a nicotinic acetylcholine receptor and comprising four cysteine residues bonded in pairs to form two disulfide bonds, wherein the N-terminus of the corresponding linear/non-cyclised conotoxin peptide is linked to the C-terminus by a peptide linker, in a vehicle which is pharmaceutically suitable for oral or enteral administration.Type: ApplicationFiled: April 3, 2007Publication date: May 13, 2010Applicant: The University of QueenslandInventors: Richard Clark, David James Craik
-
Patent number: 7687457Abstract: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the present invention provide a molecular framework for the introduction of particular amino acids or heterologous amino acid sequences to facilitate the presentation of biological activities associated with these heterologous amino acid sequences. The molecular framework of the present invention may be naturally cyclic or may be a cyclized derivative of a linear molecular or may be a linear derivative of a cyclized molecule. The present invention contemplates the use of the molecular framework with or without particular amino acids inserted or substituted thereon for the treatment of or prophylaxis of disease conditions in animals, mammals (including humans) and plants.Type: GrantFiled: May 3, 2005Date of Patent: March 30, 2010Assignee: The University of QueenslandInventors: David James Craik, Norello Lee Daly, Clements Waim-Kunduane Waine
-
Publication number: 20100068762Abstract: The present invention relates to a novel nucleic acid molecule encoding an amino acid sequence, which is capable of forming a cyclic structure. Cyclization may occur within a cell or cell membrane, or linear forms of the molecules may be circularised or partially circularised, in vitro using isolated enzyme systems or chemical means. The cyclised amino acid sequence is generally in the form of a stabilized folded structure such as acyclic knotted peptide, polypeptide or protein or functional equivalent. The nucleic acid molecules and cyclic and linear peptides are useful inter alia in the generation of molecules having animal or plant therapeutic properties, as well as in a range of diagnostic, industrial and agricultural, including horticultural, applications. Of particular importance is the use of these molecules in the protection of plants, such as crop plants, from pest and/or pathogen infestation.Type: ApplicationFiled: August 26, 2009Publication date: March 18, 2010Applicants: THE UNIVERSITY OF QUEENSLAND, HEXIMA LIMITEDInventors: David James Craik, Marilyn Anne Anderson, Cameron Victor Jennings
-
Patent number: 7592433Abstract: The present invention relates to a novel nucleic acid molecule encoding an amino acid sequence, which is capable of forming a cyclic structure. Cyclization may occur within a cell or cell membrane, or linear forms of the molecules may be circularised or partially circularised, in vitro using isolated enzyme systems or chemical means. The cyclised amino acid sequence is generally in the form of a stabilized folded structure such as a cyclic knotted peptide, polypeptide or protein or functional equivalent. The nucleic acid molecules and cyclic and linear peptides are useful inter alia in the generation of molecules having animal or plant therapeutic properties, as well as in a range of diagnostic, industrial and agricultural, including horticultural, applications. Of particular importance is the use of these molecules in the protection of plants, such as crop plants, from pest and/or pathogen infestation.Type: GrantFiled: November 3, 2000Date of Patent: September 22, 2009Assignee: The University of Queensland; Hexima LimitedInventors: David James Craik, Marilyn Anne Anderson, Cameron Victor Jennings
-
Patent number: 7312195Abstract: This invention relates to cyclised conotoxin peptides, processes for their preparation and their pharmaceutical use.Type: GrantFiled: February 7, 2005Date of Patent: December 25, 2007Assignee: The University of QueenslandInventors: David James Craik, Norelle Lee Daly, Katherine Justine Nielsen, Christopher John Armishaw, Richard Clark, Paul Francis Alewood
-
Patent number: 7001883Abstract: This invention relates to cyclized conotoxin peptides, processes for their preparation and their pharmaceutical use.Type: GrantFiled: September 14, 1999Date of Patent: February 21, 2006Assignee: The University of QueenslandInventors: David James Craik, Norelle Lee Daly, Katherine Justine Nielsen
-
Publication number: 20030158096Abstract: The present invention relates generally to a molecular framework having a cyclic structure. More particularly, the present invention provides cyclic proteins and derivatives thereof in which particular turns and other elements of the molecular structure are held in defined orientations with respect to each other. The cyclic proteins of the present invention provide a molecular framework for the introduction of particular amino acids or heterologous amino acid sequences to facilitate the presentation of biological activities associated with these heterologous amino acid sequences. The molecular framework of the present invention may be naturally cyclic or may be a cyclized derivative of a linear molecular or may be a linear derivative of a cyclized molecule. The present invention contemplates the use of the molecular framework with or without particular amino acids inserted or substituted thereon for the treatment of or prophylaxis of disease conditions in animals, mammals (including humans) and plants.Type: ApplicationFiled: April 12, 2002Publication date: August 21, 2003Inventors: David James Craik, Norello Lee Daly, Clements Waim-Kunduane Waine